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Abstract
Background: Pluripotent embryonic stem (ES) cells, which have the capacity to give rise to all tissue types in the body, show
great promise as a versatile source of cells for regenerative therapy. However, the basic mechanisms of lineage specification
of pluripotent stem cells are largely unknown, and generating sufficient quantities of desired cell types remains a formidable
challenge. Small molecules, particularly those that modulate key developmental pathways like the bone morphogenetic
protein (BMP) signaling cascade, hold promise as tools to study in vitro lineage specification and to direct differentiation of
stem cells toward particular cell types.
Methodology/ Principal Findings: We describe the use of dorsomorphin, a selective small molecule inhibitor of BMP
signaling, to induce myocardial differentiation in mouse ES cells. Cardiac induction is very robust, increasing the yield of
spontaneously beating cardiomyocytes by at least 20 fold. Dorsomorphin, unlike the endogenous BMP antagonist Noggin,
robustly induces cardiomyogenesis when treatment is limited to the initial 24-hours of ES cell differentiation. Quantitative-
PCR analyses of differentiating ES cells indicate that pharmacological inhibition of BMP signaling during the early critical
stage promotes the development of the cardiomyocyte lineage, but reduces the differentiation of endothelial, smooth
muscle, and hematopoietic cells.
Conclusions/ Significance: Administration of a selective small molecule BMP inhibitor during the initial stages of ES cell
differentiation substantially promotes the differentiation of primitive pluripotent cells toward the cardiomyocytic lineage,
apparently at the expense of other mesodermal lineages. Small molecule modulators of developmental pathways like
dorsomorphin could become versatile pharmacological tools for stem cell research and regenerative medicine.
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Introduction
Pluripotent stem cells, which are capable of self-renewal and
differentiation into multiple tissue types, show enormous potential
as a source of cells to repair damaged adult tissues [1,2]. For
example, replacement of damaged heart muscle with cells derived
from pluripotent stem cells offers hope for improving the outcomes
of millions of patients with heart failure, whose current treatments
remain largely palliative. Recent advances in reprogramming
adult somatic tissue to generate induced pluripotent stem (iPS)
cells, which possess ES-like features, have heightened the
expectation for successful regenerative therapies [3–7]. Nonethe-
less, numerous and formidable challenges must be overcome
before the regenerative potential of stem cells can be fully
harnessed. One such challenge is the development of reliable
methods and tools for generating desired cell types from
pluripotent cells.
In vitro differentiation of pluripotent ES cells provides an excellent
framework for exploring the developmental programs of a number
of distinct tissue types, including cardiac cells. Examining how ES
cells differentiate into functioning cardiomyocytes in vitro may
ultimately reveal strategies to augment the cardiogenic potential of
pluripotentstemcells,includingtheiPScells.Whilethemechanisms
by which myocardial cells are generated from ES cells are still
poorly understood, recent studies indicate that cardiomyogenesis
occurs largely through a step-wise progression of lineage commit-
ment [8], rather than simple induction of uncommitted cells by
‘‘cardiogenic’’ conditions [9]. Therefore, successful approaches to
control and promote development of cardiomyocytes from stem
cells will likely involve timely modulation of signaling pathways
PLoS ONE | www.plosone.org 1 August 2008 | Volume 3 | Issue 8 | e2904involved in embryonic cell-fate specification, such as bone
morphogenetic protein (BMP) signaling [10].
While a variety of methods can be employed to regulate
developmental pathways, selective small molecule modulators in
particular may become valuable tools for directing differentiation
of stem cells [11–13]. For example, a small molecule that can
block the effects of multiple BMP ligand subtypes and receptors
might be useful in contexts where the specific cocktail of BMPs
and cognate BMP antagonists at play is difficult to pin point.
Moreover, small molecules permit exquisite temporal control over
BMP signaling. This might be particularly important for
functional dissection of BMP signaling in complex biological
settings like in vitro ES cell differentiation, where BMP signals are
required at multiple time points to regulate a number of diverse
developmental events [10,12,14–16].
In a chemical screen for small molecules that disrupt
dorsoventral patterning in zebrafish embryos, we recently
identified dorsomorphin (6-[4-(2-Piperidin-1-yl-ethoxy)phenyl]-3-
pyridin-4-yl-pyrazolo[1,5-a]pyrimidine), also known as compound
C [17], which selectively inhibits BMP type I receptors [18]. Since
the natural BMP inhibitor Noggin has been shown to promote
mouse ES cell differentiation into cardiomyocytes [10], we
examined whether dorsomorphin could also enhance cardiomyo-
genesis. Here, we show that dorsomorphin treatment of mouse
embryonic stem (ES) cells leads to a strong expansion of the
cardiomyocytic lineage in a controlled manner. In contrast to
cardiac induction by Noggin, which requires 5 days of treatment
beginning at 3 days before the initiation of ES cell differentiation,
dorsomorphin treatment limited to the first 24-hours of differen-
tiation is sufficient for robust cardiac induction. Moreover, our
results indicate that inhibition of BMP signaling during the initial
stages of differentiation promotes cardiomyogenesis at the expense
of endothelial, smooth muscle, and hematopoietic lineages.
Results
Small molecule BMP inhibitor, dorsomorphin, induces
cardiomyogenesis in mouse ES cells
To gauge cardiomyogenesis, we used the mouse ES cell line
CGR8, which was stably transfected with a construct expressing
the red fluorescent protein gene fused to a nuclear localization
signal (DsRed-Nuc) under the alpha-myosin heavy chain (a–
MHC) promoter [19]. In this system, a–MHC expressing cells are
marked with red nuclear fluorescence, allowing a visual,
quantitative assessment of differentiating cardiomyocytes. The
cells were treated with 2 mM dorsomorphin (Figure 1A), which
effectively blocks BMP-induced SMAD activation [20], but not
AMP-activated kinase activity [17]. Based on observations by
Yuasa et al. [10], dorsomorphin was administered 3 days prior
(day 23) to the initiation of embryoid body (EB) formation.
Dorsomorphin was added with daily changes of ES media until
day 0, when EB formation was initiated in hanging drops
containing EB/differentiation medium with an additional dose
of dorsomorphin. At day 2 of EB formation, dorsomorphin was
washed out. The dorsomorphin vehicle DMSO was used as
negative control.
Under these conditions, dorsomorphin-treated aMHC-DsRed-
CGR8 cells formed large, synchronously beating areas containing
spontaneously contracting cells that expressed DsRed protein
within 12 days of differentiation (Figure 1B, Movie S1, Movie
S2). Increases in beating areas corresponded to a 20 to 30-fold
increase in the frequency of cardiomyocytes, as indicated by
DsRed-Nuc
+ or a-actinin-staining cells (see below). Dorsomor-
phin-induced cardiomyogenesis was associated with large increases
in expression of several cardiac genes, as measured by quantitative
real-time PCR (Q-PCR). Compared to controls, dorsomorphin
treatment increased expression of the early cardiac marker Nkx2.5
by 11.4-fold (Figure 1C), the cardiac myosin heavy chain gene
(Myh6) by 125-fold (Figure 1D), and the cardiac myosin light
chain 2 (Myl2) by 34.2-fold (Figure S1F) at day 10 of
differentiation. The time course for robust Myh6 and Myl2 gene
induction correlated closely with the appearance of DsRed+ cells
starting at day 8 of differentiation, confirming that DsRed-Nuc,
expressed by the stably transfected a-MHC promoter construct, is
an accurate marker of cardiomyocytic differentiation. With regular
changes in culture media, both the spontaneous contractions and
the red fluorescence could be maintained for at least 4 weeks,
suggesting that the observed cardiac phenotypes were the
consequence of a permanent differentiation program rather than
a transitory process.
Substantial increases in contracting areas were also noted with
dorsomorphin treatment of unmodified CGR8 and R1 mouse ES
cell lines maintained by three independent laboratories. Moreover,
Figure 1. The small molecule BMP inhibitor, dorsomorphin,
induces cardiomyogenesis in mouse ES cells. (A) Chemical
structures of dorsomorphin (DM), a selective BMP inhibitor, and
676489, a DM analog which inhibits VEGF/VEGFR2, but not BMP
signaling. (B) ES cells treated with dorsomorphin (DM) from day 23t o2
formed large areas of contracting cardiomyocytes that expressed
DsRed-Nuc under the a-MHC promoter by day 12 of differentiation
(right), but DMSO-treated cells did not (left). Upper panels depict
representative red fluorescence images. Lower panels show the
corresponding bright-field images. (C, D) Dorsomorphin treatment
resulted in strong increases in expression of cardiac markers Nkx2.5
(*p=0.021, **p=0.020, #p=0.0013), and Myh6 (*p=0.046, **p=0.026).
Q-PCR results represent relative expression normalized to that of
DMSO-treated cells at Day 0. Measurements were from at least three
independent experiments for each time-point.
doi:10.1371/journal.pone.0002904.g001
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inhibitor of the type-2 vascular endothelial growth factor receptor
type-2 (VEGFR2, Flk), which does not inhibit BMP signaling, did
not induce cardiomyogenesis in ES cells under this condition or
any of the additional conditions described below (data not shown).
Thus, the cardiac induction by dorsomorphin is not restricted to
the modified a-MHC-DsRed-Nuc expressing CGR8 cells, and
likely mediated by inhibition of BMP signaling.
A 96-well microtiter format for quantitative assessment
of cardiac induction by dorsomorphin treatment
A major challenge to studying in vitro cardiomyocyte develop-
ment in ES cell models is the considerable variation in
cardiomyogenesis efficiency under different culture conditions.
For example, we have found that, even in the absence of specific
chemical or molecular manipulation, the frequency of formation
of spontaneously contracting areas could vary substantially,
depending on FBS concentration and density of EBs plated per
well as well as stochastic events. To assess the impact of
dorsomorphin treatment in a more reproducible, and quantitative
manner, EB formation was initiated in 96-well microtiter plates.
Using this technique, aliquots of 500 ES cells were distributed in
uncoated round bottom microtiter plates in differentiation media,
and cells were allowed to aggregate at the bottom of each well by
gravity or by brief centrifugation. Any EB that contained visible
clusters of spontaneously contracting cells was recorded as 1
positive well. Using this method, a reproducible average of about 1
to 2% of DMSO-treated EBs were found to contract by day 12 of
differentiation (Figure 2A, Movie S3). By contrast, 94.4% of EBs
treated with 2 mM dorsomorphin from day 23 to ay 2 contracted
spontaneously by day 12 (Figure 2A). Dorsomorphin was also
effective at robustly inducing cardiomyogenesis in unmodified
CGR8 and R1 mouse ES cell lines, indicating that the
procardiogenic effects of dorsomorphin under this condition were
not cell line-restricted (Figure 2B).
Dorsomorphin treatment limited to the first 24-hours of
ES cell differentiation is sufficient for robust cardiac
induction
The 96-well microtiter format permitted quantitative assess-
ments of cardiac induction by different dorsomorphin treatment
protocols. Using this method, we determined the critical time
window for the dorsomorphin effect. We found that treatment
starting at day 22 (day 22 to 2), day 21 (day 21 to 2) and day 0
(day 0 to 2) were nearly as effective in promoting cardiac induction
as the day 23 to 2 protocol (beating frequencies ranging from 83.8
to 94.4%, Figure 2C), but dorsomorphin treatment from day 23
to 0 resulted in only 3.2% beating frequency (Figure 2C).
Importantly, dorsomorphin treatment begun at the time of EB
formation for just 24 hours (day 0 to 1) was highly effective in
promoting cardiomyogenesis, displaying beating frequencies of
89.7% (Figure 2C). Thus, the minimum time window for cardiac
induction by dorsomorphin lies within the first 24 hours of ES cell
differentiation. By contrast, in line with the previously reported
results with Noggin [10], robust cardiac induction was observed
only with Noggin treatment from day 23 to 2, but not with
Noggin treatment from day 0 to 1 of differentiation (Figure 2C).
Finally, a dose-response relationship for dorsomorphin-induced
cardiomyogenesis was determined using the 96-well EB differen-
tiation format (Figure 2D).
Dorsomorphin treatment from day 0 to 1 of differentiation,
which resulted in a 96.1% decrease in the BMP-response Id1
expression [21] in comparison to DMSO control (Figure S2), led
Figure 2. Quantitative assessment of cardiomyocyte induction
by dorsomorphin in a 96-well format. (A) Dorsomorphin (DM)
treatment in a 96-well microtiter plate format reproducibly induced
formation of beating embryoid bodies in CGR8 ES cells (94.4% of EBs,
*p,0.0001, results from at least three independent experiments
involving over 300 EBs per condition). (B) DM treatment reproducibly
induced cardiomyogenesis in R1 ES cells (91.3% of EBs, results from at
least 92 EBs). All results are compared to DMSO-vehicle treatment as
negative control. Red bars, dorsomorphin-treated. Black bars, DMSO-
treated. Error bars represent standard error. (C) Time window for
cardiomyocyte induction by dorsomorphin. DM treatments from Day
23 to 2, Day 22 to 2, Day 21 to 2, Day 0 to 2, and Day 0 to 1,
represented by red bars, were nearly equivalent in promoting formation
of beating cardiomyocytes in mouse ES cells at day 12 of differentiation.
Increases in the frequencies of beating EBs with the above DM
treatment protocols were all highly statistically significant in compar-
ison to DMSO treatment over same time periods (P,0.0001 for each
condition). Differences between the above DM treatments were not
statistically significant. In contrast, DM treatment from Days 23 to 0 did
not result in significant increase in cardiomyocyte formation compared
to DMSO control. Based on these results, the minimal temporal
requirement for cardiac induction by DM can be narrowed down to the
first 24 hours of ES cell differentiation (shown between two dotted
lines). Frequencies of DM-treated EBs that contract spontaneously by
day 12 were obtained from at least 200 EBs for each time point on three
or more separate days. Ave. denotes average percentage of EBs that
contract spontaneously. By contrast, Noggin treatment (300 ng/mL),
represented by orange bars, during the first 24 hours of differentiation
did not efficiently induce the formation of beating EBs. However, in
agreement with the prior report by Yuasa et al, Noggin treatment from
Days 23 to 2 (orange bars) efficiently induced the formation of beating
EBs. For Noggin treatment, results were obtained from 96 EBs per
condition. (D) Dose-response curve for cardiomyocyte induction by DM
treatment from Day 0 to 1. ES cells were treated with various
concentrations of DM at day 0 to 1 of differentiation, and percentages
of EBs that contract spontaneously at day 12 of differentiation were
determined. Results were then used to create a dose-response curve.
Results were obtained from at least 52 EBs per condition.
doi:10.1371/journal.pone.0002904.g002
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DMSO controls. These increases were reflected in greater areas
that immunostained for the cardiac-specific transcription factor
Nkx2.5, and the sarcomeric proteins a-Actinin, cardiac Troponin-
T and cardiac a-MHC (see below). Moreover, as observed for the
day 23 to 2 treatment, the 24-hour dorsomorphin treatment was
associated with very large increases in the expression of cardiac-
specific genes Nkx2.5 and Myh6, as measured by Q-PCR (up to
5.8-fold and 100-fold induction, respectively; Figure 3A, B).
Consistent with both the immunostaining and Q-PCR results,
western blots with cardiac a-MHC antibody showed markedly
higher cardiac a-MHC protein levels in dorsomorphin-treated
EBs than in controls (Figure 3C).
Cardiac induction by dorsomorphin treatment during the initial
24 hours of differentiation was quantified by two distinct
approaches using two ES cell lines. In the first, day 12 EBs from
a-MHC-DsRed CGR8 cells were dissociated with trypsin and
stained with DAPI, followed by microscopic examination to count
the total number of cells (DAPI+) and the DsRed+ cardiomyo-
cytes. Using this method, an average of 38.4% of dorsomorphin-
treated cells were DsRed+, while 1.8% of DMSO-treated cells
were DsRed+, representing an approximately 21-fold increase in
the relative abundance of cardiomyocytes with dorsomorphin
treatment (Figure 3D). Next, the cardiomyocyte induction in the
parental CGR8 cell lines was measured by FACS analysis. On day
12, EBs treated with dorsomorphin or DMSO were dissociated,
and stained with anti-a-Actinin and secondary AlexaFluor-488
antibodies. FACS analyses showed that approximately 35 to 40%
of dorsomorphin-treated ES cells were positive for sarcomeric
protein a-Actinin, whereas only 1 to 2% of DMSO-treated cells
were positive for a-Actinin, representing an approximately 30-fold
induction in frequency of a-Actinin+ cells (Figure 3E).
Characterization of cardiomyocytes induced by
dorsomorphin treatment
To confirm that the large synchronously contracting areas of
DsRed+ cells induced by the dorsomorphin treatment were
composed of cardiomyocytes, dorsomorphin EBs were fixed at day
12 and processed for immunostaining with specific antibodies
against several known cardiac markers. In dorsomorphin-treated
EBs, large areas that immunostained for the sarcomeric proteins a-
Actinin, cardiac Troponin-T (c-TnT), and cardiac a-Myosin
Heavy Chain (a-MHC) are readily observed (Figure 4A, B).
Moreover, Nkx2.5 immunostaining colocalized with a-Actinin, c-
TnT, and a-MHC+ areas, confirming that large patches of
cardiomyocytes were induced by dorsomorphin treatment
(Figure 4A, B). Confocal microscopy confirmed the sarcomeric
organization of a-Actinin, c-TnT, and a-MHC staining in
dorsomorphin-induced cardiomyocytes (Figure 4B). By contrast,
in control EBs, areas that immunostained for a-Actinin, c-TnT,
and a-MHC were rare, and foci comprised of few isolated cells,
lacking sarcomeric organization (Figure 4C).
Pharmacological BMP inhibition promotes
cardiomyogenesis at the expense of other mesoderm-
derived cell lineages
To gain insight into how dorsomorphin treatment promotes
cardiomyogenesis, we examined expression of several markers of
mesoderm-derived lineages in ES cells treated with 2 mMD Ma t
day 0 to 1 and compared them to DMSO-treated cells. In contrast
to the earlier finding with Noggin, which dramatically increased
expression of the mesoderm marker Brachyury T (BryT) at day 3,
dorsomorphin treatment (day 0 to 1) significantly reduced BryT
expression at day 3 (Figure 5A). However, with dorsomorphin
treatment, significant levels of BryT expression persisted to day 4,
when BryT expression was extinguished in controls (Figure 5A).
Dorsomorphin treatment caused even more striking changes to the
expression of Mesp1, one of the earliest known markers of cardiac
progenitor cells [22]. With dorsomorphin treatment, onset of
significant Mesp1 expression did not occur until day 4, one day
later and at moderately lower levels than in controls (Figure 5B).
Thus, in contrast to Noggin treatment or other reported
manipulations that promote cardiomyogenesis in ES cells [10–
12,23], dorsomorphin treatment does not simply increase peak
expression of mesoderm makers per se, but rather delays the onset
of their expression.
Figure 3. Dorsomorphin treatment during the initial 24 hours
of ES cell differentiation robustly induces cardiomyogenesis.
(A, B) Dorsomorphin (DM) treatment from day 0 to 1 of differentiation
resulted in strong increases in expression of cardiac markers Nkx2.5
(*p=0.003, **p=0.0019, #p=0.0001), and Myh6 (*p=0.023,
**p=0.029, #p=0.0089). All results are compared to DMSO-vehicle
treatment as negative control. Red bars, DM-treated. Black bars, DMSO-
treated. Error bars represent standard error. Q-PCR results represent
relative expression normalized to that of DMSO-treated cells at day 0.
Measurements were obtained from at least three independent
experiments for each time-point. (C) Western blot showing markedly
higher levels of the cardiac a-Myosin Heavy Chain (a-MHC) protein in
DM-treated ES cells on day 10 in comparison to DMSO-treated controls.
Antibody against a-Tubulin was used as loading control. (D)D M
treatment greatly increased the number of fluorescent nuclei that
expressed DsRed as a percentage of total cells (DAPI+) at day 12 (error
bars, standard error; p,0.0001 vs. DMSO control). Results from trypsin
dissociated cells from 11 DM-treated EBs and 14 DMSO-treated controls.
(E) Representative FACS analysis showing an approximately 30-fold
increase in the fraction of a-actinin+ cells following DM treatment vs.
DMSO controls.
doi:10.1371/journal.pone.0002904.g003
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mesodermal markers affect the differentiation of other lineages of
mesodermal origin, we analyzed the timing and quantified the
levels of expression of blood, endothelial and smooth muscle cell-
specific markers. In contrast to cardiomyocyte markers, we found
that dorsomorphin treatment from day 0 to 1 decreased the
expression of the hematopoietic progenitor marker Gata1
(Figure 5C) and the smooth muscle-specific myosin heavy chain
gene Myh11 (Figure 5D). In addition, dorsomorphin treatment
led to sustained decreases in the expression of the vascular marker
Flk-1 (Vegfr2) from day 3 to 8 (Figure 5E). Whereas Flk-1
expression is not endothelium-restricted [14], this result, together
with the reduced vascular endothelial-cadherin (VE-Cad) expres-
sion at days 6 and 8 (Figure 5F), suggests that dorsomorphin
treatment decreases endothelial cell differentiation. Similar results
were seen for day 23 to 2 dorsomorphin treatment (Figure S1A
to E). Thus, pharmacological blockade of BMP signaling during
the initial stages of ES cell differentiation appears to promote
formation of pre-cardiac mesodermal cells at the expense of
endothelial, smooth muscle and hematopoietic lineages.
Discussion
Small molecules that selectively modulate developmental
pathways hold promise as versatile tools for dissecting signaling
pathways involved in lineage commitment of pluripotent stem cells
and for directing stem cell differentiation toward desired cell types
[11,12]. Here, we have used dorsomorphin, a recently described
small molecule inhibitor of BMP signaling, to reproducibly and
substantially induce cardiomyogenesis in mouse ES cells. Dorso-
morphin treatment during the first 24 hours of differentiation was
sufficient for robust cardiac induction at the expense of other
mesoderm-derived lineages.
Our findings are generally in line with those obtained using the
endogenous BMP antagonist Noggin [10]; however, several
important differences are worth noting. First, whereas the Noggin
application must begin prior to the initiation of EB formation for a
Figure 4. Dorsomorphin treatment promotes the formation of
large areas comprised of cardiomyocytes. (A) Dorsomorphin-
treated ES cells formed larger areas of contracting cardiomyocytes that
immunostained for the sarcomeric proteins cardiac Troponin-T (c-TnT),
a-Actinin and a-cardiac myosin heavy chain (a-MHC) at day 10 (Green,
left panels). The areas that immunostained for sarcomeric proteins also
immunostained for the cardiac-specific transcription factor Nkx2.5 (Red,
middle panels), confirming that these regions are comprised mainly of
cardiomyocytes. Merged images are on the right. (B) Merged 406
confocal images showing the details of sarcomeric protein and Nkx2.5
immunostaining (right, a-actinin/Nkx2.5; middle, c-troponin-T/Nkx2.5;
right, a-cardiac MHC/Nkx2.5). DM-treated cells showed many cardio-
myocytes with organized sarcomeric structures. (C)1 0 6 images of
DMSO-treated cells. In control conditions, cells that immunostain for
sarcomeric proteins and Nkx2.5 are rare and typically form much
smaller foci without discernable sarcomeric organization. The panels
depict representative immunofluorescence images.
doi:10.1371/journal.pone.0002904.g004
Figure 5. Dorsomorphin treatment promotes cardiomyogen-
esis at the expense of other mesodermal lineages. (A)
Dorsomorphin treatment during the first 24 hours of ES cell differen-
tiation (from day 0 to 1) blunted the induction of BryT expression at day
3 (*p=0.0016), but resulted in higher BryT expression at day 4, in
comparison to controls (**p=0.017). (B) Dorsomorphin treatment
caused similar, yet even more striking, changes in Mesp1 expression
(*p,0.0001, **p=0.0107). In addition, dorsomorphin treatment result-
ed in significant decreases in (C) Gata1 expression at days 4 to 8
(*p=0.0382, **p=0.0044, and #p=0.0019), in (D) MyH11 expression at
days 8 and 10 (*p=0.0032 and **p=0.0040), in (E) Flk-1 expression at
day 3 to 6 (*p=0.0002, **p=0.0092, and #p=0.0021), and in (F) VE-
Cadherin (VE-cad; vascular endothelium-cadherin) expression at day 4
to 8 (*P=0.0076, **p=0.0364, and #P=0.0153). All results are
compared to DMSO control. Red bars, dorsomorphin-treated. Black
bars, DMSO-treated. Q-PCR results were obtained from at least three
independent experiments. Error bars, standard error.
doi:10.1371/journal.pone.0002904.g005
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dorsomorphin treatment begun at the time of EB formation and
continued for just 24 hours was able to induce cardiomyogenesis
very efficiently. Second, in contrast to Noggin, dorsomorphin
treatment did not increase the peak expression of the early
mesoderm marker BryT at day 3 of differentiation, but rather
delayed the temporal pattern of its expression. Dorsomorphin
treatment also led to a delay in the onset of the cardiac progenitor
marker Mesp1 expression.
It is possible that the overall duration and later persistence of BryT
and Mesp1 expression, not their transient peak levels, better reflect
the number of BryT+ or Mesp1+ cells generated. This, together with
the fact that dorsomorphin treatment limited to the initial 24 hours of
differentiation was sufficient for robust cardiac induction, lead us to
propose that dorsomorphin acts on a very primitive pluripotent cell
type to promote the cardiomyogenic program.
Together with increases in the expression of cardiac-specific
genes and decreases in the expression of endothelial, smooth
muscle and hematopoietic markers, the dorsomorphin-induced
delay in the temporal expression patterns of BryT and Mesp1 is
consistent with a substantial shift in the developmental repertoire
of mesodermal cells toward the formation of cardiac precursor
cells, which arise subsequent to the formation of the hemangio-
blastic population [8,14]. Based on the prior report with Noggin
[10], we hypothesize that the dorsomorphin effect is cell-
autonomous, acting directly on primitive pluripotent cells to
increase the proportion that becomes committed to the cardiac
lineage, consequently leaving less for endothelial, smooth muscle
and hematopoietic development. Although the detailed mecha-
nism by which dorsomorphin promotes the formation of
committed cardiac precursors is yet to be determined, our findings
provide additional support for the interconnection between the
myocardial and the noncardiac mesodermal lineages as they
diverge from a common progenitor [14,25,27–30], and suggest the
critical role of BMP signaling in regulating this process.
Distinct effects of Noggin and dorsomorphin on ES cell
differentiation may reflect intrinsic differences between the small
molecule dorsomorphin and protein-based BMP antagonists.
Dorsomorphin efficiently induces cardiomyogenesis when added
at the onset of differentiation, whereas robust induction by Noggin
is observed only when it is added prior to EB formation. This
difference may reflect the small molecule’s ability to readily
penetrate multiple cell layers in developing EBs. In contrast,
endogenous antagonists like Noggin may not gain full access to
cells once the EB is formed. The differences could also arise from
the fact that dorsomorphin appears to target multiple type-I BMP
receptor subtypes [18], whereas Noggin’s effects may be limited to
antagonizing specific BMP ligands. Finally, a caveat to consider
with a small molecule like dorsomorphin is the potential impact on
off-target effects. For instance, the substantial reduction in peak
BryT expression with dorsomorphin treatment could reflect the
small molecule’s effects on non-BMP signaling that negatively
influence early mesoderm formation. Development of small
molecules which are more selective for BMP signaling will be
essential to clarify this issue.
In summary, we have utilized a selective small molecule
inhibitor of BMP signaling, an important developmental pathway,
to promote differentiation of primitive pluripotent cells toward
cardiac cells. While it remains to be seen whether small molecule
inhibitors of BMP signaling can also induce cardiac differentiation
of other stem cell types, including the induced pluripotent stem
(iPS) cells made from adult somatic tissue, the inherent advantages
of small molecules like dorsomorphin could prove valuable for
translation of recent stem cell advances into regenerative therapies.
Dorsomorphin, which unlike endogenous BMP antagonists does
not exhibit limited selectivity for ligand subtypes [20], can expand
empiric efforts to modulate stem cell differentiation even in
contexts where the specific cocktail of active BMPs is unknown.
Moreover, precise temporal control afforded by a small molecule
could prove to be critical for functional dissection of BMP
signaling in complex biological contexts like organogenesis, where
BMP pathway function at multiple developmental nodes with
often divergent effects. Finally, because small molecules are
relatively inexpensive, can penetrate many cell layers, and may
be orally bioavailable, pharmacologic modulators of key develop-
mental pathways will prove to be useful, not just to control
differentiation of pluripotent stem cells in vitro, but also to enhance
the regenerative potential of resident stem cells in vivo.
Materials and Methods
Cell culture
Murine ES cell lines, CGR8 and R1, were grown in feeder-free
conditions as monolayers. The CGR8 ES cell line was transfected
with the nuclear-localized red fluorescent protein (DsRed-Nuc)
gene that is expressed under the cardiac a-myosin heavy chain
promoter (the a-MHC promoter vector was kindly provided by J.
Robbins and M. Anderson, and pDsRed-Nuc vector was
purchased from Clontech). CGR8 cells were maintained in
GMEM (Sigma-Aldrich) supplemented with 10% FBS (Gibco),
2m ML-glutamine, (Cellgro), 0.05 mM 2-mercaptoethanol (Sig-
ma-Aldrich), and 200 U/ml murine LIF (Chemicon Internation-
al). R1 cells were maintained in High Glucose DMEM (Gibco)
supplemented with 15% FBS, 2 mM L-glutamine, 16nonessential
amino acids, 100 U/ml penicillin-100 mg/ml streptomycin (Cell-
gro), 0.05 mM 2-mercaptoethanol, 1 mM sodium pyruvate
(Sigma-Aldrich), and 200 U/ml murine LIF. Both cell lines were
cultured on 0.2% gelatin-coated dishes. Every 24 hours, cells were
washed in 16 PBS and culture media was replaced. Cells were
passaged when confluence reached 50–60% to preserve the
undifferentiated phenotype.
Initiation of Dorsomorphin Treatment
For experiments in which dorsomorphin treatment was begun
prior to EB formation, ES cell cultures at 10% confluence were
treated with ES media supplemented with 2 mM dorsomorphin
(Compound C, Sigma-Aldrich) dissolved in DMSO (Sigma-
Aldrich). Cells treated with media containing an equivalent
amount of DMSO served as a negative control. ES media
containing either dorsomorphin or DMSO was changed daily for
three days. DMSO-treated cells had similar outcomes to control
untreated cells, indicating that DMSO had no effect on ES cell
growth and differentiation.
ES cell Differentiation
After ES cell treatment with dorsomorphin or DMSO for three
days (on Day 0), ES cells were trypsinized and embryoid bodies
(EBs) were generated by the three-dimensional hanging drop
method (Day 0). Briefly, EBs were grown in hanging drops for two
days (Day 0 to Day 2), each of which initially consisted of 500 cells
in 19 mL of EB differentiation media. The EB differentiation
media was composed of IMDM (Gibco) supplemented with 20%
FBS, 1.6 mM L-glutamine, 16 nonessential amino acids,
0.08 mM 2-mercaptoethanol, and either 2 mM dorsomorphin or
DMSO. For R1 cells, differentiation media additionally contained
1 mM sodium pyruvate. At day 2 of differentiation (Day 2),
treatment with dorsomorphin or DMSO was discontinued. The
EBs were transferred to uncoated Petri dishes and suspended in
Dorsomorphin Cardiac Induction
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EBs were moved to gelatin-coated 6-well plates, allowed to attach
and incubated in differentiation media until Day 14. In certain
experiments, differentiated cells were kept in culture for several
weeks for observation of long-term effects. Throughout this time,
the media was replaced every 48–72 hours. Each day, differen-
tiating cell clusters were microscopically examined for the presence
of contracting cardiomyocytes and, in the case of engineer CGR8
cells, red fluorescence.
A second culture technique was used to form embryoid bodies,
which allowed us to quantify the number of contracting EBs. The
ES cells were grown in accordance with the aforementioned
methods. Rather than constructing hanging drops on day 0,
aliquots of cells were distributed in uncoated 96-well round bottom
plates, and 100 mL of dorsomorphin- or DMSO-containing
differentiation media was added to each well. Beginning on day
2, the media was replaced every 48–72 hours with differentiation
media lacking dorsomorphin or DMSO. EBs were microscopically
examined for contracting cardiomyocytes on days 8 through 12.
Any well containing spontaneously beating cells was recorded as 1
positive result.
For experiments in which dorsomorphin treatment was begun
at the time of EB formation, EBs were generated by the
aforementioned methods in the presence of dorsomorphin or
DMSO. At specified times, treatment with dorsomorphin or
DMSO was discontinued.
Quantification of DsRed+ cells
Embryoid bodies (EB) were grown on gelatin-coated plates for
12 days following dorsomorphin or DMSO treatment. On day 12,
EBs expressing DsRed-Nuc under the a-MHC promoter were
dissociated with trypsin treatment, stained with 49-6-Diamidino-2-
phenylindole (DAPI), and 2 mL aliquots were placed on cover slips
to count the DsRed+ nuclei and the total DAPI stained nuclei
under a fluorescence microscope.
FACS analysis
EBs were dissociated into single cell suspensions after trypsin-
ization. Following a wash with 10%FBS/DMEM, cells were
permeabilized with 0.05% saponin/PBS buffer for 20 minutes on
ice. Cells were then stained with an a-Actinin antibody (Sigma;
1:100dilution in 10%FBS/DMEM) for 1 hour. Following washes
with 10%FBS/DMEM, cells were incubated with an anti-mouse
secondary antibody conjugated to AlexaFluor-488 (1:200 dilution
in 10%FBS/DMEM) for 30 minutes in dark. After additional
washes in 10%FBS/DMEM, cells were resuspended in 300 mL
10%FBS/DMEM and analyzed on the 5-laser BD LSRII FACS
instrument.
Immunostaining and confocal microscopy
EBs treated with dorsomorphin or DMSO (day 0,1) were
plated at day 4 on glass cover slip culture chambers coated with
1% gelatin. At day 10, EBs were fixed in 5% formaldehyde at
room temperature for 30 minutes, and then permeabilized with
0.2% Triton X-100 in PBS. After blocking with 1 mg/ml BSA in
PBS, cells were incubated with mouse monoclonal anti-a-Actinin
(Sigma), mouse cardiac alpha-myosin heavy chain (Abcam), or
mouse cardiac Troponin T (Santa Cruz) antibodies along with
goat Nkx2.5 antibody (Santa Cruz) at concentrations recommend-
ed by the manufacturers. After overnight incubation, cells were
washed several times with PBS and then incubated with the
AlexaFluor-488-conjugated rabbit anti-mouse IgG (Molecular
Probes) and Cy3-conjugated-AffiniPure rabbit anti-goat IgG
(Jackson Immuno). Immunostaining images were obtained using
both a Leica inverted microscope (106) and a Zeiss inverted LSM
510 confocal microscope (406).
Quantitative real-time PCR
Cells were harvested on days 0, 2, 3, 4, 6, 8, 10, 12 of EB
differentiation and stored at 280uC in cell lysis buffer RLT (Qiagen).
Three independent samples were collected for each time point
studied. Total RNA was extracted using the RNeasy Mini Kit
according to the manufacturer’s instructions and treated with RNase-
free DNase I (Qiagen). First-strand cDNA was synthesized with the
SuperScript III First-Strand Synthesis SuperMix for qRT-PCR
(Invitrogen). Using cDNA as template, TaqMan real-time PCR
assays was performed in triplicates on the ABI Prism 7900 HT
sequence detection system (Applied Biosystems) according to the
manufacturer’s instructions. Data were normalized to GAPDH, and
levels of gene expression were normalized to that of Day 0 DMSO-
treated cells. The following TaqMan probe and primer sets (Applied
Biosystems) were used: Id1 (Mm00775963_g1), nkx2.5
(Mm00657783_m1), myh6 (Mm00440354_m1), myl2
(Mm00440384_m1), brachyury T (Mm00436877_m1), flk-1
(Mm00440099_m1), myh11 (Mm00443013_m1), gata1
(Mm00484678_m1), ve-cadherin (Mm00486938_m1), mesp1
(Mm00801883_g1), and GAPDH (Mm99999915_g1).
Western Blotting
Lysates of EBs on day 10 were separated by SDS/PAGE and
transferred onto PVDF membrane. The a-MHC protein was
detected by Odyssey system (Li-Cor bioscience) following
incubation with mouse a-MHC antibody (Abcam, 1:500 dilution)
and IRDye 800CW-conjugated goat anti-mouse IgG (Li-Cor
Bioscience, 1:2000 dilution). Mouse a-tubulin antibody (Abcam,
1:2000) was used as a loading control.
Supporting Information
Figure S1 Dorsomorphin treatment from day 23 to 2 promotes
cardiomyogenesis at the expense of other mesodermal lineages. (A)
Dorsomorphin treatment (from day 23 to 2) blunted the induction
of BryT expression at day 3 of differentiation (*p=0.01), but
resulted in higher BryT expression at day 4, in comparison to
controls (**p=0.0424). Dorsomorphin treatment resulted in
significant decrease in (B) Flk-1 expression at day 3 to 6
(*p=0.0353 and #p=0.0237), in (C) VE-Cadherin (VE-cad;
vascular endothelium-cadherin) expression at day 4 and 6
(*P=0.0042 and **P=0.0018), in (D) MyH11 expression at days
8 and 10 (*p=0.0104 and #p,0.0001), and in (E) Gata1
expression at days 4, 6 and 8 (*p=0.0016, **p=0.0003 and
#p=0.0452). (F) Dorsomorphin treatment (day 23t o2 )
increased cardiac myosin light chain 2 (Myl2) expression at day
10 by 34.2-fold over control. All results compared to DMSO
control. Red bars, dorsomorphin-treated. Black bars, DMSO-
treated. Q-PCR results, except for Myl2, were obtained from at
least three independent experiments. Error bars, standard error.
Found at: doi:10.1371/journal.pone.0002904.s001 (0.65 MB TIF)
Figure S2 Dorsomorphin (DM) treatment of ES cells efficiently
blocks activation of the BMP-target gene Id1. Treatment of mouse
ES cells with 2 mM DM from day 0 to 1 of differentiation resulted
in a 96.1% reduction in the expression levels of the BMP-target
gene Id1 at day 1 (*p,0.0001). All results are compared to
DMSO-vehicle treatment as negative control. Red bars, dorso-
morphin-treated. Black bars, DMSO-treated. Error bars represent
standard error. Q-PCR results represent relative expression
normalized to that of DMSO-treated cells at day 0. Results were
obtained from at least three independent experiments.
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Movie S1 Spontaneously contracting focus of cardiomyocytes
expressing DsRed-Nuc protein under the a-MHC promoter
formed from dorsomorphin-treated ES cells at day 12 of
differentiation.
Found at: doi:10.1371/journal.pone.0002904.s003 (1.15 MB AVI)
Movie S2 Phase contrast movie of spontaneously contracting
foci of cardiomyocytes formed from dorsomorphin-treated ES cells
on a gelatin-coated plate.
Found at: doi:10.1371/journal.pone.0002904.s004 (0.89 MB AVI)
Movie S3 Spontaneously contracting EB formed from dorso-
morphin-treated ES cells on a 96-well microtiter plate.
Found at: doi:10.1371/journal.pone.0002904.s005 (0.81 MB AVI)
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